Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
about
DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancerNanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy.Assessing the effect of a nude mouse model on nanoparticle-mediated gene delivery.The achievement of ligand-functionalized organic/polymeric nanoparticles for treating multidrug resistant cancer.Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death.Cytokines in immunogenic cell death: Applications for cancer immunotherapy.Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier.The new era of nanotechnology, an alternative to change cancer treatment.B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity.Elimination of established tumors with nanodisc-based combination chemoimmunotherapy.Dual-Energy CT Imaging of Tumor Liposome Delivery After Gold Nanoparticle-Augmented Radiation Therapy.Trial watch: Immunogenic cell death induction by anticancer chemotherapeuticsLiposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response
P2860
Q37276254-A14D7C40-E7FB-40A5-BBCC-01440FF179BBQ37739064-20D398C7-200B-405B-91FD-8E3A29ECA46DQ38750076-79624586-F741-4011-A627-51C774E68DE6Q38809044-0D026F74-01BC-4371-B4D9-8EF500B26F56Q39397337-7F2C3AEE-BA24-46FC-AEBB-328177A06A51Q39397491-BBEFA2DD-547B-488B-9300-C5BD7AB69B76Q41078784-2723187E-7BFE-48EA-A19D-513E8F6B9D00Q42370576-D78A1C26-0F85-4397-8337-07537C982531Q50545382-67AFA5A6-D5E4-43D9-9AE3-B2D20B2DB664Q55044963-BBF1D267-3059-4C79-8A74-574670B7B4CAQ55341737-88E01785-ED22-4C18-BEF1-82248F0300D3Q56594845-A66D6D71-5E14-406D-B8B0-4E28F2DB1E58Q59133970-4DD33AE5-0BCD-4255-94C5-ACCEA1D51280
P2860
Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Doxil synergizes with cancer i ...... ses in syngeneic mouse models.
@ast
Doxil synergizes with cancer i ...... ses in syngeneic mouse models.
@en
type
label
Doxil synergizes with cancer i ...... ses in syngeneic mouse models.
@ast
Doxil synergizes with cancer i ...... ses in syngeneic mouse models.
@en
prefLabel
Doxil synergizes with cancer i ...... ses in syngeneic mouse models.
@ast
Doxil synergizes with cancer i ...... ses in syngeneic mouse models.
@en
P2093
P2860
P1433
P1476
Doxil synergizes with cancer i ...... ses in syngeneic mouse models.
@en
P2093
Ching Ching Leow
Jon Chesebrough
Jonathan Rios-Doria
Leslie Wetzel
Nicholas Durham
Nicholas Holoweckyj
Raymond Rothstein
Robert Hollingsworth
P2860
P304
P356
10.1016/J.NEO.2015.08.004
P577
2015-08-01T00:00:00Z